A5068044000- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Sympathectomy and Hyperhidrosis Treatments
- Human Health and Disease
- Spondyloarthritis Studies and Treatments
- Traumatic Ocular and Foreign Body Injuries
- Dermatological and COVID-19 studies
- Cytokine Signaling Pathways and Interactions
- Immunodeficiency and Autoimmune Disorders
- Acne and Rosacea Treatments and Effects
- Dermatologic Treatments and Research
- Immunotoxicology and immune responses
- Nasolacrimal Duct Obstruction Treatments
- Chemical and Physical Studies
- Rheumatoid Arthritis Research and Therapies
- melanin and skin pigmentation
Guz "Tul'skiy Oblastnoy Onkologicheskiy Dispanser
2017-2022
The article represents the results of a prospective analysis 28 patients with severe plaque psoriasis and advanced psoriatic arthritis insufficient response to previous systemic therapy, treated certolizumab pegol at Tula Regional Clinical Dermatovenerologic Dispensary in years 2017–2019. Certolizumab demonstrated high sustained efficacy improving skin disease manifestations arthritis. Safety profile was consistent therapeutic class.
The article presents clinical cases of treatment acute generalized pustular psoriasis (GPP) with the use an interleukin IL-17A inhibitor, secukinumab, which showed a remarkable response almost complete disappearance pustules after first injection. To best our knowledge, there are limited data in literature on evaluating effectiveness therapy genetically engineered drugs GPP.
A growing understanding of the cellular and molecular mechanisms inflammation in psoriasis psoriatic arthritis opens way to treatment these diseases with help new small molecules, associated blockade intracellular signal transduction. Jaqinus®/Xeljanz® (tofacitinib, “Pfizer”) is first oral inhibitor Janus kinases for chronic moderately severe plaque psoriasiswhich was approved usage Russia. The authors also present own local data regarding tofacitinib 10 20 mg/day by short course group 13...
Hematidrosis is a rare disease. Isolated cases are described in the literature, which makes it impossible to study etiology and pathogenesis of The most convincing assumptions about role emotional stress clinical manifestations author presents his own 2-year observation girl who periodically had bleeding from nose ear canal.
The work represents the prospective cohort analysis of patients with psoriasis treated certolizumab pegol (CZP) at Tula Regional Clinical Dermatovenerologic Dispensary in years 2017–2019, who achieved remission and discontinued CZP real-time observation patients. remained sustained after discontinuation (mean drug-free was 42 weeks). Patients had not responded to systemic therapy prior treatment demonstrated good response methotrexate cyclosporin A, which suggests modulation immune by pegol....
In this work we discuss a case of Bullosus pemfigoid (B.P.) developed after pneumonia caused by new coronavirus disease COVID‑19 in patient with psoriasis. Provided description is supported the data histological and serologic analysis, lgG epithelial basement membrane was detected to antigen ВР230-CF ВР180-NC16A.
The article discusses the common pathogenetic pathways of autoimmune skin diseases – psoriasis and vitiligo. Currently proposed treatments for vitiligo do not significantly reduce or completely restore pigmentation. use adalimumab 6 years in a patient suffering from psoriasis, psoriatic arthritis (PsA), thyroiditis made it possible to control activity PsA, also contributed regression depigmentation foci. biologic disease-modifying antirheumatic drug therapy this group patients order achieve...